GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has announced its Q1 FY27 financial results, with revenue up 15% YoY to INR 924 crores and PAT increasing by 24% to INR 253 crores. The company's General Medicines portfolio grew strongly, with key promoted brands outperforming the market. The company has also made progress in strengthening its supply chain resilience and is preparing for key pipeline launches.

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the quarter ended June 30, 2026, along with changes in management and other business updates.

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has presented its investor presentation, highlighting its Q1 FY27 financial performance, which saw revenue growth of 15% and EBITDA margin expansion of 50 bps, driven by execution excellence and portfolio transformation. The company's key brands maintained their competitive performance, and the vaccine segment continues to lead the market.

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of new securities on stock exchanges.

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has held its 101st Annual General Meeting on June 30, 2026, and has announced the voting results for various resolutions. The company has approved all the resolutions, including the appointment of a new director, declaration of dividend, and ratification of remuneration to auditors. The voting results are available on the company's website and the National Securities Depository Limited's website.

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has received a Demand Notice from the National Pharmaceutical Pricing Authority for overcharging Rs. 1,22,91,163 and interest of Rs. 2,31,20,862, totaling Rs. 3,54,12,025. The company will file an appeal against the demand order.